Literature DB >> 26512180

Generalized Pustulosis Diagnosed as Acute Generalized Exanthematous Pustulosis: Tzanck Smear and Pathological Evaluation of the Pustule Roof Can Provide Evidence for Early Diagnosis.

Soo Min Kim1, Yee Jeong Kim2, Nam Joon Cho1.   

Abstract

Entities:  

Year:  2015        PMID: 26512180      PMCID: PMC4622900          DOI: 10.5021/ad.2015.27.5.616

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: An 83-year-old male patient presented with a 1-day history of fever (38.6℃) and pruritic rash over the whole body. He had history of diabetes and cerebral infarction, but no drug allergies or psoriasis. He had been hospitalized due to common bile duct stone with cholangitis and pneumonia. Piperacillin/tazobactam had been prescribed for 19 days before the emergence of his skin rash, and levofloxacin and vancomycin had been added 10 days and 7 days before the rash appeared, respectively. All antibiotics were discontinued after he developed skin eruption; imipenem/cilastatin replaced them. Three days later, generalized pustules appeared over the erythema (Fig. 1). His lips were eroded; palms and soles were spared. Laboratory studies showed neutrophilia (15,562/mm3; before rash, 3,999/mm3), elevated blood urea nitrogen (43 mg/dl) and C-reactive protein (>20 mg/dl), and thrombocytopenia (32,000/mm3); transaminase levels were normal. Eosinophilia, atypical lymphocytes, and lymphadenopathy were absent. The differential diagnosis included acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), generalized pustular psoriasis (GPP), staphylococcal scalded skin syndrome (SSSS), and hypersensitivity syndrome. He refused skin biopsy; Tzanck smear and frozen section of pustule roof were done. The Tzanck smear showed many neutrophils, eosinophils, and lymphocytes without bacterial cocci (Fig. 2A). The histopathology of the pustule roof demonstrated subcorneal pustules with marked neutrophilic and eosinophilic infiltration without immunofluorescence (Fig. 2B). Bacterial cultures from blood and pustule contents were negative. From the clinical and pathologic findings, AGEP was strongly suspected. Although the patient's skin lesions cleared and his laboratory abnormalities were normalized with conservative treatment in 14 days, he died of underlying infection. Generalized pustulosis accompanied by fever and neutrophilia, a characteristic manifestation of AGEP, sometimes presents a diagnostic challenge. While dysfunction of internal organs is unusual in AGEP, systemic involvements have been reported1. When systemic manifestations develop, wide spectrum of diseases including infections, inflammations, and drug reactions are considered. Early diagnosis is important in avoiding unnecessary investigations and determining proper treatment options. AGEP is mostly caused by drugs2. In this patient, the causative drug was uncertain because multiple antibiotics were prescribed before he developed skin eruption. One of the key histopathological features that distinguishes AGEP from GPP is the presence of eosinophils, both in the subcorneal/intraepidermal pustules and dermis (in 32%~58% and 81%~95% of cases, respectively) on skin biopsy34. Contrariwise, in GPP, eosinophils are not observed or scarcely found4. Tzanck smear is rapid, noninvasive, and useful in sites and cases for which skin biopsy is difficult to obtain5. In SSSS, Tzanck smear and pathology of blister roof show uppermost epidermal cells without inflammatory cells5. In TEN, blister roof reveals subepidermal splitting with full-thickness necrosis of epidermis; Tzanck smear demonstrates necrotic basal keratinocytes with fibroblasts and inflammatory cells5. To our knowledge, there has been no report on Tzanck smear and pathological evaluation of the pustule roof in AGEP. In this patient, Tzanck smear and the pathological evaluation of the pustule roof revealed eosinophils, which are a histopathological characteristic of AGEP. Although Tzanck smear and the pathological evaluation of the pustule roof may not be replacements for skin biopsy, these can provide evidence for the early diagnosis of generalized pustulosis while the results of other tests are pending.
Fig. 1

Generalized pustules arising on an erythematous background on the trunk.

Fig. 2

(A) Tzanck smear showing many polymorphonuclear leukocytes, mainly neutrophils (↖) and a few eosinophils (↗) (Diff Quik, ×400). (B) The pustule roof showing subcorneal separation with mixed inflammatory cell infiltration composed of neutrophils and a few eosinophils (↗) (H&E, ×400).

  5 in total

Review 1.  The practical use of cytology for diagnosis in dermatology.

Authors:  E Ruocco; G Brunetti; M Del Vecchio; V Ruocco
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-06-09       Impact factor: 6.166

2.  Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature.

Authors:  Min Jee Choi; Hei Sung Kim; Hyun Jeong Park; Chul Jong Park; Jeong Deuk Lee; Jun Young Lee; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

3.  The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis.

Authors:  Sylvia H Kardaun; Hilde Kuiper; Vaclav Fidler; Marcel F Jonkman
Journal:  J Cutan Pathol       Date:  2010-08-25       Impact factor: 1.587

4.  Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients.

Authors:  C Hotz; L Valeyrie-Allanore; C Haddad; S Bouvresse; N Ortonne; T A Duong; S Ingen-Housz-Oro; J C Roujeau; P Wolkenstein; O Chosidow
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

5.  The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases.

Authors:  S Halevy; S H Kardaun; B Davidovici; J Wechsler
Journal:  Br J Dermatol       Date:  2010-12       Impact factor: 9.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.